Filing summary
Entity mismatch: The supplied filing is Priveterra Acquisition Corp.’s Form 10-Q, not an AEON Biopharma, Inc. filing. It reports the quarter ended March 31, 2022. Priveterra identifies itself as a blank-check company seeking a business combination; it had not begun operating or generated operating revenue.
Financial performance and position
- Revenue and margins: No operating revenue. Operating costs were $389,073, versus $200,863 in Q1 2021; operating loss was $389,073. Operating margins are not meaningful without revenue.
- Net income: $2.77 million, down from $6.32 million in Q1 2021. The 2022 result included a $3.03 million noncash gain from changes in warrant fair value and $129,586 of trust-account interest; these more than offset operating costs. Q1 2021 included a $7.17 million warrant fair-value gain and $655,046 of offering costs allocated to warrants.
- Cash flow: Operating cash use was $411,669, compared with $554,518 in Q1 2021. Cash fell $331,169 during Q1 to $166,243. Investing activities provided $80,500, reflecting a trust withdrawal for taxes; there was no Q1 financing cash flow.
- Liquidity and assets: The trust account held approximately $276.1 million at March 31, 2022, primarily in U.S. Treasury bills. Operating cash was $166,243; total assets were $276.65 million. The filing reports current liabilities of $791,843.
- Debt and other obligations: No working-capital loan borrowings were outstanding. The $9.66 million deferred underwriting discount is payable only if a business combination is completed. Warrant liability was $4.35 million, down from $7.38 million at December 31, 2021.
Changes, outlook, and risks
- Compared with Q1 2021, net income was lower, operating costs were higher, and cash from operations remained negative. The prior-year comparison includes IPO-related activity and a larger warrant fair-value gain.
- Management intended to complete a business combination by February 11, 2023, the stated end of the 24-month combination period. Failure to do so would require winding up and redeeming public shares from the trust, subject to the filing’s terms. No business-combination guidance or target-specific outlook is provided.
- Management stated that limited operating liquidity, ongoing costs, and mandatory liquidation if no transaction is completed raise substantial doubt about the company’s ability to continue as a going concern. It intended to complete a transaction before the deadline.
- Disclosure controls were deemed ineffective because of a material weakness in accounting for complex financial instruments. Management described planned remediation, including enhanced review and access to technical accounting expertise.
- The filing discusses potential effects of COVID-19 and the Russia-Ukraine conflict but says their specific impacts were not determinable. It also notes that proposed SEC SPAC rules could increase transaction costs, time, and execution risk. No legal proceedings or material subsequent events were reported.
Important facts to verify
- Confirm the issuer: this filing is for Priveterra Acquisition Corp., not AEON Biopharma, Inc.
- Reconcile reported working-capital deficits: the filing gives different amounts in different sections ($284,498 in the notes and $223,315 in MD&A); the balance-sheet figures imply a different amount.
- Assess funding needs and the likelihood of completing a business combination before February 11, 2023, given the going-concern warning and low operating cash.
- Verify the treatment and valuation of warrants, including the $3.03 million noncash gain and the Level 3 private-warrant valuation.
- Monitor remediation of the material weakness and the status and terms of any proposed transaction, including deferred underwriting fees and public-share redemptions.